Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-18 of 18 for your search:
Start Over
Vaccine Therapy with or without Polysaccharide-K in Treating Patients with Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7866, NCI-2013-01377, 135, 7866/135, NCT01922921
Vaccine Therapy, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 0418, NCI-2013-00498, UNC-LCCC-0418, NCT00266110
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Stage IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J0947, NCI-2010-02004, NA_00024527, JHOC-J0947, GENENTECH-JHOC-J0947, NCT00971737
Combined Vaccine Therapy in Treating Patients with Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-09138, NCI-2011-00920, NCT01376505
Vaccine Therapy in Treating Patients with Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor 2 Positive Cancers
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00034612, NCI-2013-00525, NCT01526473
Vaccine Therapy and Basiliximab in Treating Patients With Stage IV Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 03111, NCI-2013-00879, NCT01660529
Vaccine Therapy in Treating Patients with HER2-Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0016, NCI-2013-01564, 130016, P12990, NCT01730118
HER2-Pulsed Type-1 Polarized Autologous Dendritic Cell Vaccine in Treating Patients With Stage I-III HER2 Positive Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 26113, NCI-2014-00878, 818561, NCT02110199, NCT02061423
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ID-LV305-2013-001, NCI-2014-01153, NCT02122861
Vaccine Therapy in Treating Patients with HER2-Negative Stage III-IV Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9140, NCI-2014-01070, 137, NCT02157051
Mammaglobin-A DNA Vaccine in Treating Patients with Newly Diagnosed Breast Cancer Undergoing Endocrine Therapy before Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201407100, NCI-2014-01457, 14-x092, NCT02204098
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ONT-10-104, NCI-2014-02599, NCT02270372
Personalized DNA Vaccine in Treating Patients with Triple-Negative Breast Cancer following Chemotherapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201505074, NCI-2015-00827, NCT02348320
Personalized Vaccine Therapy in Treating Patients with Triple-Negative Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201506113, NCI-2015-01050, NCT02427581
Vaccine Therapy in Treating Patients With Breast Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 12911, NCI-2010-00461, Breast 37, NCT00892567
Vaccine Therapy in Treating Patients with Stage IB-IIIA Breast Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Breast41, NCI-2014-02151, 1134, NCT01532960
Dendritic Cell Vaccine and Gemcitabine Hydrochloride in Treating Patients with Metastatic Breast Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE 3113, NCI-2014-00265, 046203, 3113_, NCT02479230
Start Over